Article
Neil Carleton and Priscilla F. McAuliffe
Redefining Ovarian Cancer Care with Biomarkers
Clips
Summary
Exploring ovarian cancer, biomarkers HRD & RB1, and how Labcorp innovations are advancing precision oncology.
In this episode of Labcorp Perspectives Oncology, host Dr. Rebecca Previs sits down with colleague and pathologist Dr. Kyle Strickland to explore the complexities of ovarian cancer and the evolving science shaping its diagnosis and treatment.
Together, they discuss how ovarian cancer is often misunderstood as a single disease, the importance of accurately classifying its subtypes, and the critical role biomarkers like HRD and RB1 play in improving outcomes. Dr. Strickland shares his latest research on RB1, explains how HRD testing is reshaping patient care, and highlights Labcorp’s advancements with OmniSeq Insight, designed to provide clinicians with deeper insights into tumor biology. Listeners will gain a clearer understanding of how these scientific developments are transforming precision oncology and opening the door to new possibilities for ovarian cancer patients.
Related Topics
You May Also Like
Neil Carleton and Priscilla F. McAuliffe
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Jonathan H. Cheng, Justin W. Tiulim, Sheng Zhou, Anthony El-Khoueiry and Jorge Nieva
Mandatory Research Biopsy Requirements Delay Initiation of Clinical Trials
Article
Kirill Peskov, Ivan Azarov, Lulu Chu, Veronika Voronova, Yuri Kosinsky, Gabriel Helmlinger
Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
Article
Kirsten B Goldberg, Gideon M Blumenthal, Amy E McKee and Richard Pazdur
The FDA Oncology Center of Excellence and Precision Medicine
Podcast
